BioLife Solutions (BLFS) EVP has 515 shares withheld for taxes

Rhea-AI Filing Summary

BioLife Solutions EVP and Chief Scientific Officer Mathew Aby J. reported a small share disposition related to taxes, not an open-market trade. On the release of restricted stock units, 515 shares of common stock were withheld by the company at $19.27 per share to satisfy his tax obligations. After this tax-withholding event, he directly holds 390,167 shares of BioLife Solutions common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mathew Aby J.

Role EVP & Chief Scientific Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	515	$19.27	$10K

Holdings After Transaction: Common Stock — 390,167 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 515 shares Withholding price per share: $19.27 per share Shares held after transaction: 390,167 shares

3 metrics

Shares withheld for taxes 515 shares Tax withholding on restricted stock unit release

Withholding price per share $19.27 per share Value used for tax-withholding disposition

Shares held after transaction 390,167 shares Direct holdings following tax withholding

Key Terms

restricted stock units, tax withholding obligations, Form 4

3 terms

restricted stock units financial

"arose upon the release of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy tax withholding obligations"

Form 4 regulatory

"reported a Form 4 for EVP and Chief Scientific Officer"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mathew Aby J.

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WASHINGTON 98021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/08/2026		F		515	D	$19.27(1)	390,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Remarks:

	/s/ Aby J. Mathew	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BioLife Solutions (BLFS) report for Mathew Aby J.?

BioLife Solutions reported a Form 4 for EVP and Chief Scientific Officer Mathew Aby J. documenting 515 common shares withheld to cover tax obligations from restricted stock unit release, rather than an open-market sale or purchase.

How many BioLife Solutions shares were withheld for taxes in this BLFS Form 4?

The filing shows 515 BioLife Solutions common shares were withheld. These shares were retained by the company to satisfy Mathew Aby J.’s tax withholding obligations triggered by the vesting of restricted stock units.

At what price were the BioLife Solutions (BLFS) shares valued for the tax withholding?

The 515 withheld shares were valued at $19.27 per share. This price is used in the Form 4 to quantify the tax-withholding disposition related to the release of restricted stock units for the executive.

How many BioLife Solutions (BLFS) shares does Mathew Aby J. hold after this transaction?

After the tax-withholding disposition, Mathew Aby J. directly holds 390,167 shares of BioLife Solutions common stock. This illustrates that the 515 withheld shares represent a very small portion of his total reported holdings.

Was the BLFS insider transaction an open-market sale by Mathew Aby J.?

No, the transaction was not an open-market sale. The Form 4 footnote explains the 515 shares were withheld by BioLife Solutions solely to satisfy tax withholding obligations arising from restricted stock unit vesting.